City of Hope

California Institute of Technology

William Marsh Rice University

Materia, Inc.

The University of Texas System

Baylor College of Medicine

City of Hope, a Non-profit Charitable Organization

Jacob Berlin

Gregory Copeland

Kathleen Elison

Hurik Muradyan

Robert H Grubbs

James Mitchell Tour

Yann Schrodi

Karen S Aboody

Rachael Mooney

Desiree Van Haute

Tom Haber

Pamela Tiet

Ian C Stewart

Changhuei Yang

Haowen Ruan

Raymond Weitekamp

Daisuke Sano

Ashley Leonard

Krishnan Thyagarajan

Alexander J Annala

Jeffrey N Myers

Thomas Andrew Kent

Robia G Pautler

Pengpeng Cao

Wafa Abidi

Daniela Marcano

Yvonne Cornejo

Tam Pham

Taeko Inoue

Brittany Bitner

Yiming Weng

The disclosure provides, inter alia, compositions including cell-nanoparticle constructs and drug loaded nanoparticles, and methods for their use in the treatment of cancer. Also provided are unmodified cisplatin molecules encapsulated by silica nanoparticles, and their use in the treatment of cancer.

Nanoparticle-cell construct with platinum anti-cancer agent

Disclosed herein, inter alia, are compositions and methods of modulating macrophage activity. Provided is a method of treating a disease (e.g., a macrophage-associated disease, autoimmune disease, inflammatory disease, or a cancer of an organ in the intraperitoneal cavity), the method including intraperitoneally administering to a subject in need thereof a therapeutically effective amount of a nanoparticle composition or pharmaceutical composition. Provided is a silica nanoparticle non-covalently bound to a plurality of nucleic acids, wherein the silica nanoparticle has a net positive charge in the absence of the plurality of nucleic acids. Provided is a pharmaceutical composition including a nanoparticle composition as described herein, and a pharmaceutically acceptable excipient.

Compositions and methods of modulating macrophage activity

Provided herein are functionalized nanoparticle compositions and methods of using the same. The functionalized nanoparticles provided include a nuclease cleavage site and are, inter alia, useful for the formation of nanoparticle aggregates and detection of nuclease activity through nanoparticle aggregate formation.

Nucleic acid-functionalized nanoparticles

Disclosed herein, inter alia, are nanoparticle compositions (e.g., silica nanoparticles) including insoluble drug nanocrystals and methods of using the same for treating cancer.

Silica nanoparticle with an insoluble drug

A magnetic field controlled guidestar for focusing light deep inside scattering media using optical phase conjugation. Compared with the optical and ultrasonic field, the magnetic field has an exceptional penetration depth. The magnetic particle guidestar has a high light-tagging efficiency, good biocompatibility, and a small diameter which enables a sharp and bright focusing deep inside biological tissue. This new method can benefit a wide range of biomedical applications including deep-tissue imaging, neural modulation, and targeted photothermal and photodynamic therapies.

Focusing light inside scattering media with magnetic particle guided wavefront shaping

Provided herein are encoded split pool libraries useful, inter alia, for forming highly diverse and dense arrays for screening and detection of a variety of molecules.

Chemically encoded spatially addressed library screening platforms

A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition, a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject.

Encapsulated diagnostics and therapeutics in nanoparticles&#x2014;conjugated to tropic cells and methods for their use

Provided herein are compositions and methods of preparing nanoparticle aggregates.

Chemically-linked nanoparticles

The present disclosure is directed to processes comprising irradiating an aggregate of chemically bonded or otherwise associated nanoparticles with a light source capable of providing multiphoton excitation, the light source directed at a focal point volume including the aggregate and having sufficient energy to disrupt or fuse the aggregate within the focal point volume to form nanoscale deposits of the nanoparticles.

Multiphoton induced direct aggregate scribing

In some embodiments, the present invention provides methods of treating oxidative stress in a subject by administering a therapeutic composition to the subject. In some embodiments, the therapeutic composition comprises a carbon nanomaterial with anti-oxidant activity. In some embodiments, the anti-oxidant activity of the carbon nanomaterial corresponds to ORAC values between about 200 to about 15,000. In some embodiments, the administered carbon nanomaterials include at least one of single-walled nanotubes, double-walled nanotubes, triple-walled nanotubes, multi-walled nanotubes, ultra-short nanotubes, graphene, graphene nanoribbons, graphite, graphite oxide nanoribbons, carbon black, oxidized carbon black, hydrophilic carbon clusters, and combinations thereof. In some embodiments, the carbon nanomaterial is an ultra-short single-walled nanotube that is functionalized with a plurality of solubilizing groups. In some embodiments, the carbon nanomaterial is a polyethylene glycol functionalized hydrophilic carbon cluster (PEG-HCC). In some embodiments, the administered therapeutic compositions of the present invention may also include an active agent or targeting agent associated with the carbon nanomaterial. Additional embodiments of the present invention pertain to the aforementioned carbon nanomaterial compositions for treating oxidative stress.

Use of carbon nanomaterials with antioxidant properties to treat oxidative stress

The present invention pertains to therapeutic compositions that comprise: (1) a nanovector, (2) an active agent; and (3) a targeting agent, wherein the active agent and the targeting agent are non-covalently associated with the nanovector. The present invention also pertains to methods of treating various conditions in a subject by utilizing the above-described therapeutic compositions. Methods of making the therapeutic compositions are also a subject matter the present invention.

Therapeutic compositions and methods for targeted delivery of active agents

The invention relates to ruthenium alkylidene complexes having an N-heterocyclic carbene ligand comprising a 5-membered heterocyclic ring having a carbenic carbon atom and at least one nitrogen atom contained within the 5-membered heterocyclic ring, wherein the nitrogen atom is directly attached to the carbenic carbon atom and is substituted by a phenyl ring, and wherein the phenyl ring has a hydrogen at either or both ortho positions and is substituted at at least one ortho or meta position. The invention also relates to an olefin metathesis reactions and particularly to the preparation of tetra-substituted cyclic olefins via a ring-closing metathesis.

Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins

Growing community of inventors

Monrovia, CA, United States of America

Jacob Berlin